Hepatocyte growth factor promotes migration of human myeloma cells.
about
Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaElevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma.Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.c-Met signaling promotes IL-6-induced myeloma cell proliferation.HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway.Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.Which B-cell subset should we target in lupus?Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis.Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsPrognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance
P2860
Q35736729-9BD5F09D-111B-46BB-A5B9-DD9F9A3C6B22Q36413501-D50814B3-CEFA-475C-A5E2-949718D24BF8Q36776906-085E678D-04FB-42D7-AEE9-8B459C39E0DEQ36973696-8A82B096-AEAA-4DE9-8719-23C07219EA22Q37137157-A6168A4C-31C5-446D-B413-7A72911DD39AQ37398728-CDF31B3A-9E26-45C3-840F-9BF8999EB18EQ37608433-779442E5-A2AF-46FC-AFD5-D9AC9B3660F3Q38476204-1118CBEC-B110-4673-B885-D857C3CBBC7EQ38848444-F94EF878-7611-4C76-AF34-4547B34CC90BQ39109310-365C9DD2-E8B5-40AE-AE07-3BA311B7C6C6Q39174836-02382317-818B-4740-A72A-26885846E061Q39395884-128A2655-476D-487C-8B11-DE91D565AA5CQ39888526-6ED31FCD-2B07-41C7-85C7-F382809A8341Q42374498-2F44E837-D900-4A01-8FFD-A1BD98B148DFQ43483788-8BDC3E27-E4F5-4698-B1E8-2CB1C1D89DEFQ43647817-BACCEDE8-3236-4495-95B6-7463D37F65F7Q44643220-B603B271-EBA1-4EC6-B2E8-75948BA1611BQ46005728-E521A992-31B5-4788-B201-8BD79391EBB2Q46331197-676C0C08-0EF0-42BF-98DE-52FCA5BBE3D1Q54448123-819EAFB2-0174-40C2-B6D0-BAC61B85697CQ58164582-4E660E6A-E687-4C33-83FD-7BF4CD63CFB1Q58914769-54B577F5-852D-406B-9510-36CCF027A03E
P2860
Hepatocyte growth factor promotes migration of human myeloma cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Hepatocyte growth factor promotes migration of human myeloma cells.
@en
type
label
Hepatocyte growth factor promotes migration of human myeloma cells.
@en
prefLabel
Hepatocyte growth factor promotes migration of human myeloma cells.
@en
P2093
P50
P356
P1433
P1476
Hepatocyte growth factor promotes migration of human myeloma cells.
@en
P2093
Anders Sundan
Anders Waage
Randi Utne Holt
Unn-Merete Fagerli
Vadim Baykov
P304
P356
10.3324/HAEMATOL.11867
P577
2008-03-06T00:00:00Z